文献速递心律失常心力衰竭与心肌病

室性心动过速消融时机对植入式心律转复除颤器患者预后的影响:多中心随机PARTITA试验结果

Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial.
PubMed 文献 · Circulation · 2022-04-03

PARTITA试验为两阶段前瞻性多中心随机临床研究,纳入缺血性或非缺血性扩张型心肌病且符合ICD适应症的患者,在首次适当电击后随机分配至立即消融组或继续标准治疗组。结果显示消融组主要终点(全因死亡或心衰恶化住院)发生率显著低于对照组(4% vs 42%,HR 0.11,P=0.034),且死亡率更低、ICD电击更少。

要点

  • 首次ICD适当电击后2个月内行室速消融可显著降低死亡或心衰恶化住院风险。
  • 消融组无死亡,对照组死亡8例(33%),差异有统计学意义。
  • 消融组ICD电击发生率9%,显著低于对照组的42%。

核心结论

  • 首次适当ICD电击后行室速消融与死亡或心衰恶化住院复合终点风险降低相关,并降低死亡率和ICD电击次数。

研究设计与样本

  • 两阶段前瞻性多中心随机临床试验,阶段A观察至首次适当电击,阶段B按1:1随机分配至立即消融(电击后2个月内)或继续标准治疗。
  • 阶段A纳入517例缺血性或非缺血性扩张型心肌病且符合ICD适应症的患者,56例(11%)在中位随访2.4年期间接受适当电击,其中47例(84%)参与阶段B。

主要发现

  • 中位随访24.2个月后,主要终点在消融组发生1/23(4%),对照组10/24(42%),HR 0.11(95%CI 0.01-0.85),P=0.034。
  • 消融组无死亡,对照组死亡8例(33%),P=0.004。
  • 消融组心衰恶化住院1例(4%),对照组4例(17%),P=0.159。
  • 消融组ICD电击发生率9%,对照组42%,P=0.039。
  • 结果满足预设的贝叶斯优效性终止标准(>99%后验概率)。

关键数值与推荐

  • 主要终点为全因死亡或心衰恶化住院的复合终点。
  • 消融组主要终点4% vs 对照组42%,HR 0.11(95%CI 0.01-0.85),P=0.034。
  • 消融组死亡0% vs 对照组33%,P=0.004。
  • 消融组ICD电击9% vs 对照组42%,P=0.039。
  • 除记录到房性快速心律失常外,不允许使用胺碘酮。

临床怎么用

  • 对于缺血性或非缺血性扩张型心肌病ICD患者,在首次适当电击后应考虑行室速消融以改善预后。

局限性

  • 阶段B因首次中期分析结果而提前终止,样本量较小(消融组23例,对照组24例)。
  • 阶段A中仅11%的患者接受适当电击,阶段B参与率84%,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimal timing for catheter ablation of ventricular tachycardia is an important unresolved issue. There are no randomized trials evaluating the benefit of ablation after the first implantable cardioverter defibrillator (ICD) shock. METHODS: We conducted a 2-phase, prospective, multicenter, randomized clinical trial. Patients with ischemic or nonischemic dilated cardiomyopathy and primary or secondary prevention indication for ICD were enrolled in an initial observational phase until first appropriate shock (phase A). After reconsenting, patients were randomly assigned 1:1 in phase B to immediate ablation (within 2 months from shock delivery) or continuation of standard therapy. The primary end point was a composite of death from any cause or hospitalization for worsening heart failure. Amiodarone intake was not allowed except for documented atrial tachyarrhythmias. On July 23, 2021, phase B of the trial was interrupted as a result of the first interim analysis on the basis of the Bayesian adaptive design. RESULTS: Of the 517 patients enrolled in phase A, 154 (30%) had ventricular tachycardia, 56 (11%) received an appropriate shock over a median follow-up of 2.4 years (interquartile range, 1.4-4.4), and 47 of 56 (84%) agreed to participate in phase B. After 24.2 (8.5-24.4) months, the primary end point occurred in 1 of 23 (4%) patients in the ablation group and 10 of 24 (42%) patients in the control group (hazard ratio, 0.11 [95% CI, 0.01-0.85]; P=0.034). The results met the prespecified termination criterion of >99% Bayesian posterior probability of superiority of treatment over standard therapy. No deaths were observed in the ablation group versus 8 deaths (33%) in the control group (P=0.004); there was 1 worsening heart failure hospitalization in the ablation group (4%) versus 4 in the control group (17%; P=0.159). ICD shocks were less frequent in the ablation group (9%) than in the control group (42%; P=0.039). CONCLUSIONS: Ventricular tachycardia ablation after first appropriate shock was associated with a reduced risk of the combined death or worsening heart failure hospitalization end point, lower mortality, and fewer ICD shocks. These findings provide support for considering ventricular tachycardia ablation after the first ICD shock. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01547208.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Della Bella P, Baratto F, Vergara P, et al. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022. PMID: 35369700. doi:10.1161/CIRCULATIONAHA.122.059598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。